mHealth

Remote monitoring solution for cytokine release syndrome paves the way for more consistent patient care, a deeper understanding of immune responses, ultimately widening patient access to life-saving immunotherapy and reducing recruitment barriers in clinical trials.

The full value of clinical data will only be unlocked by redesigning how it’s captured, connected, and applied to accelerate decisions, improve trials, and better serve patients.

How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.

As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous heart data while reducing patient burden.

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs are evolving beyond testing to become strategic partners in clinical trial success.

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving meaningful impact for patients.

Clinical trial liaisons rather serve as experts in their therapeutic areas and as clinical trial specialists to provide a suite of strategic advantages to benefit a study.

Key considerations in deploying fit-for-purpose digital health technologies in drug development.

Evolving mindsets are opening the door for industry to utilize new mediums for understanding patients.

Digitalization has been progressively facilitating increased access to trials by helping alleviate logistical burdens, but not much is known about how these tools can address the needs of patients with multiple chronic conditions.

Moving beyond the pill to extend the value being delivered to patients.

The role of the cloud in realizing the practical benefits of mHealth in clinical trials.

In this interview, Dr. David Lee Scher adds his perspective on how digital health is changing in both healthcare and clinical trial settings.

The Duke Margolis Center for Health Policy (DMCHP) recently collaborated with the FDA to release an mHealth action plan entitled "Mobilizing mHealth Innovation for Real-World Evidence Generation."

Austin Speier, VP of Emerging Technologies at Precision for Medicine, recently spoke about mHealth regulatory pathways at PanAgora’s Mobile Innovations Summit, and will elaborate further in this Q&A interview.